However, the combined PD-L2 signals did not exceed the risk associated with the cancer cell-specific PD-L2 signal in ER+ breast cancer (HR, 2.0; 95% CI, 1.4 to 2.9; P < .001; Table 2). This evidence concerns the gene PDCD1LG2 and breast cancer.